FDA, Tirzepatide

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...
The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...
The federal agency authorized the use of the Eli Lilly & Co. weight loss drug for “treatment of moderate to severe ...
Approved in 2022 for type 2 diabetes and in 2023 for chronic weight management along with diet and exercise, tirzepatide is ...
The US Food and Drug Administration re-issued a decision first made by the agency in October that a shortage of the diabetes/weight-loss medication tirzepatide is over.
The nod, just months after topline results from SURMOUNT-OSA came out, makes it the first drug approved for this indication.
The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...
A recent case published in the journal ACG CASE REPORTS JOURNAL found a possible risk of colonic ischemia caused by the usage ...
Harvey Fierstein shared how he lost 120 pounds. He says he is a “great believer” in weight loss drugs like Zepbound and ...